Drug Profile

CIN 110

Alternative Names: CIN-110; JNJ-9321

Latest Information Update: 05 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Janssen Sciences Ireland UC
Developer CinFina Pharma
Class Obesity therapies; Peptides
Mechanism of Action Neuropeptide Y receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Obesity

Most Recent Events

03 Nov 2024 Efficacy, pharmacokinetics and adverse event data from phase I trial in Obesity released by CinFina Pharma
26 Mar 2024 Phase-I clinical trials in Obesity (In volunteers) in USA (SC)
26 Mar 2024 US FDA approves IND application for CIN-110 in Obesity

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com